PMID- 38282099
OWN - NLM
STAT- MEDLINE
DCOM- 20240321
LR  - 20240321
IS  - 1096-9101 (Electronic)
IS  - 0196-8092 (Linking)
VI  - 56
IP  - 3
DP  - 2024 Mar
TI  - Comparison of 755-nm picosecond alexandrite laser versus 1064-nm Q-switched 
      Nd:YAG laser for melasma: A randomized, split-face controlled, 2-year follow-up 
      study.
PG  - 263-269
LID - 10.1002/lsm.23763 [doi]
AB  - OBJECTIVES: Pulsed laser treatment of melasma has shown some promising results. 
      To compare the effectiveness and safety of 755-nm picosecond alexandrite laser 
      (PSAL) fitted with diffractive lens array (DLA) versus 1064-nm Q-switched 
      neodynimum:yttrium aluminum garnet laser (QSNYL) for the treatment of melasma. 
      METHODS: We conducted a randomized, split face controlled, 2-year follow-up 
      study. Each face was divided into two parts, each side receiving three treatments 
      with either PSAL or QSNYL at 1 month intervals. Modified Melasma Area Severity 
      Index scores (mMASI), pain scores, patient satisfaction and adverse events were 
      recorded. In vivo reflectance confocal microscopy (RCM) images were acquired. 
      RESULTS: Twenty subjects were enrolled and three dropped out. At 6 months, mMASI 
      scores were significantly lower than baseline for QSNYL sides (p = 0.022), with 
      no statistically significant difference between PSAL sides before and after 
      treatment, PSAL sides versus QSNYL sides, or patient satisfaction scores. QSNYL 
      treatment was associated with less pain (p = 0.014). No serious adverse events 
      were reported. In the PSAL sides RCM showed a large number of dendritic 
      melanocytes infiltrated in the dermis at 2 weeks and 4 weeks after treatment. Ten 
      patients (58.82%) reported recurrence or exacerbation at 2-year follow-up with no 
      statistically significant difference between the two lasers. CONCLUSIONS: QSNYL 
      demonstrated short term clinical efficacy for melasma, but did not provide any 
      additional benefit compared to PSAL with DLA. QSNYL was associated with less 
      pain. There was a high recurrence rate at 2-year follow-up. RCM allowed the 
      detection of cellular changes in melasma lesions.
CI  - (c) 2024 Wiley Periodicals LLC.
FAU - Zhou, Yanjun
AU  - Zhou Y
AD  - Department of Dermatology, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Li, Yong
AU  - Li Y
AD  - Department of Dermatology, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Hamblin, Michael R
AU  - Hamblin MR
AUID- ORCID: 0000-0001-6431-4605
AD  - Laser Research Centre, Faculty of Health Science, University of Johannesburg, 
      Doornfontein, South Africa.
FAU - Wen, Xiang
AU  - Wen X
AUID- ORCID: 0000-0003-0512-6502
AD  - Department of Dermatology, West China Hospital, Sichuan University, Chengdu, 
      China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20240128
PL  - United States
TA  - Lasers Surg Med
JT  - Lasers in surgery and medicine
JID - 8007168
RN  - 0 (alexandrite)
RN  - OW5102UV6N (Beryllium)
SB  - IM
MH  - Humans
MH  - Follow-Up Studies
MH  - *Lasers, Solid-State/therapeutic use
MH  - *Melanosis/radiotherapy
MH  - Treatment Outcome
MH  - Pain
MH  - *Beryllium
OTO - NOTNLM
OT  - 1064-nm Q-switched Nd:YAG laser
OT  - diffractive lens array
OT  - melasma: split face controlled trial, 755-nm picosecond alexandrite laser
OT  - reflectance confocal microscopy
EDAT- 2024/01/29 00:42
MHDA- 2024/03/21 12:43
CRDT- 2024/01/28 23:43
PHST- 2024/01/09 00:00 [revised]
PHST- 2023/10/19 00:00 [received]
PHST- 2024/01/16 00:00 [accepted]
PHST- 2024/03/21 12:43 [medline]
PHST- 2024/01/29 00:42 [pubmed]
PHST- 2024/01/28 23:43 [entrez]
AID - 10.1002/lsm.23763 [doi]
PST - ppublish
SO  - Lasers Surg Med. 2024 Mar;56(3):263-269. doi: 10.1002/lsm.23763. Epub 2024 Jan 
      28.